Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 4,551 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Experimental treatment Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effects of ProFoveate on Reducing Self-Stimulating Behaviors

NCT02088047
View directory record Official record
Conditions
Autism Spectrum Disorders, Normal Hearing, Normal Intelligence, Exhibit Self- Stimulating or Ritualistic Behaviors
Interventions
ProFoveate
Device
Lead sponsor
University of Arkansas
Other
Eligibility
10 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 4, 2026, 6:07 PM EDT
Withdrawn Not applicable Interventional

TrueRelief Efficacy for Supraspinatus Tendonitis

NCT05184985
View directory record Official record
Conditions
Supraspinatus Tendinitis, Shoulder Pain
Interventions
TrueRelief device, Sham TrueRelief device
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)

NCT00239915
View directory record Official record
Conditions
Persistent Developmental Stuttering
Interventions
Pagoclone
Drug
Lead sponsor
Pharmacology Research Institute
Other
Eligibility
18 Years to 65 Years
Timeline
2005 – 2006
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

NCT03485014
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
Exparel
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
12 Years to 16 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Not applicable Interventional

Increasing Adherence to Oral Appliance Therapy for Obstructive Sleep Apnea

NCT05038215
View directory record Official record
Conditions
Obstructive Sleep Apnea, Adherence, Patient
Interventions
adherence promotion techniques, Routine Care
Behavioral · Procedure
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 4, 2026, 6:07 PM EDT
Terminated Phase 1 Interventional Results available

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

NCT02003573
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
decitabine iv, volasertib iv infusion
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
65 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 4, 2026, 6:07 PM EDT
Recruiting Not applicable Interventional

Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD

NCT06883266
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
transcranial direct current stimulation (tDCS), Sham (No Treatment)
Device
Lead sponsor
Sanford Health
Other
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 4, 2026, 6:07 PM EDT
Withdrawn Phase 2 Interventional

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

NCT03035630
View directory record Official record
Conditions
Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
Interventions
Avelumab, Sunitinib
Drug
Lead sponsor
Guru Sonpavde
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia

NCT05233761
View directory record Official record
Conditions
Insomnia
Interventions
Defined CBD, Placebo
Drug
Lead sponsor
Defined Research
Industry
Eligibility
25 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 4, 2026, 6:07 PM EDT
Not listed Phase 2 Interventional

Long- Term Transcranial Direct Current Stimulation in Parkinson's Disease

NCT03638531
View directory record Official record
Conditions
Parkinson Disease
Interventions
Anodal tDCS, SHAM tDCS
Device
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
60 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

NCT00863239
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ribavirin, Locteron™ (controlled-release interferon alpha 2b), PEG-Intron™
Drug
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Chula Vista, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 4, 2026, 6:07 PM EDT
Completed No phase listed Observational Results available

Adolescents' Well-being in Community-based Treatment Versus Residential Treatment

NCT06498427
View directory record Official record
Conditions
Adolescent Well-Being, Mental Disorders, Severe
Interventions
Not listed
Lead sponsor
Outcome Referrals, Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Framingham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Not applicable Interventional Results available

Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa

NCT04600375
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Verbal consultation, Written Action Plan
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 89 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 4, 2026, 6:07 PM EDT
Terminated Phase 3 Interventional Results available

Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)

NCT00926575
View directory record Official record
Conditions
Acute Gastrointestinal Graft vs Host Disease
Interventions
oral beclomethasone 17,21-dipropionate, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Buffalo, New York • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

NCT04780841
View directory record Official record
Conditions
Hyperkalemia
Interventions
RDX013, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 85 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Coral Gables, Florida • Miami Lakes, Florida • Miami Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 4, 2026, 6:07 PM EDT
Not yet recruiting Not applicable Interventional

Effects of Core Strengthening Exercises for Treating TMD

NCT07226505
View directory record Official record
Conditions
Temporomandibular Joint Dysfunction, TMD, TMJ Internal Derangement, Myofascial Pain
Interventions
Experimental: Group 1: Core Strengthening, Group 2: Standard TMD PT
Behavioral
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 4, 2026, 6:07 PM EDT
Recruiting Phase 2 Interventional

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

NCT05790239
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy
Drug · Behavioral
Lead sponsor
Stephen Robert Marder
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions

NCT01157169
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Phase 3 Interventional

A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

NCT00067951
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone/metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
49
States / cities
Anniston, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 4, 2026, 6:07 PM EDT
Completed Not applicable Interventional

CompARing Long terM Outcomes in Chronic Stroke Survivors Across Investigational Assessments Following a Prescribed Upper Extremity Exercise Program

NCT05659875
View directory record Official record
Conditions
Chronic Stroke
Interventions
Standard Occupational Therapy Arm Exercise Program
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 4, 2026, 6:07 PM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 4, 2026, 6:07 PM EDT
Recruiting Not applicable Interventional

CARED : A Novel Rapid Treatment Paradigm for Depression

NCT07507370
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Intermittent Theta Burst Stimulation (iTBS), Transcranial Alternating Current Stimulation (tACS), Psychotherapy, Sham (Placebo) Transcranial Alternating Current Stimulation (tACS)
Device · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 4, 2026, 6:07 PM EDT
Terminated Phase 4 Interventional Results available

Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint

NCT01045694
View directory record Official record
Conditions
Arthritis Multiple Joint
Interventions
Botulinum Toxin Type A, Steroid - Triamcinolone Acetonide, Lidocaine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 4, 2026, 6:07 PM EDT